IMPACT BIOMEDICAL INC(NYSEARCA:IBO) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 0 out of 10 to IBO. IBO was compared to 198 industry peers in the Pharmaceuticals industry. IBO may be in some trouble as it scores bad on both profitability and health. IBO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IBO has reported negative net income.

IBO had a negative operating cash flow in the past year.

1.2 Ratios

With a Return On Assets value of -121.79%, IBO is not doing good in the industry: 79.29% of the companies in the same industry are doing better.

Looking at the Return On Equity, with a value of -580.23%, IBO is doing worse than 78.28% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-121.79%
ROE	-580.23%
ROIC	N/A

ROA(3y)-48.88%

ROA(5y)N/A

ROE(3y)-207.06%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IBO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for IBO remains at a similar level compared to 1 year ago.

The debt/assets ratio for IBO is higher compared to a year ago.

2.2 Solvency

IBO has an Altman-Z score of -3.40. This is a bad value and indicates that IBO is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of IBO (-3.40) is comparable to the rest of the industry.

IBO has a Debt/Equity ratio of 2.08. This is a high value indicating a heavy dependency on external financing.

IBO has a Debt to Equity ratio of 2.08. This is in the lower half of the industry: IBO underperforms 75.25% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.08
Debt/FCF	N/A
Altman-Z	-3.4

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

IBO has a Current Ratio of 0.25. This is a bad value and indicates that IBO is not financially healthy enough and could expect problems in meeting its short term obligations.

IBO has a Current ratio of 0.25. This is amonst the worse of the industry: IBO underperforms 92.93% of its industry peers.

IBO has a Quick Ratio of 0.25. This is a bad value and indicates that IBO is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of IBO (0.25) is worse than 91.92% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.25
Quick Ratio	0.25

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for IBO have decreased strongly by -509.26% in the last year.

EPS 1Y (TTM)-509.26%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-2093.02%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IBO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IBO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IMPACT BIOMEDICAL INC

NYSEARCA:IBO (4/22/2025, 8:11:16 PM)

After market: 0.425 +0 (+0.16%)

0.4243

+0 (+1.1%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners1.89%

Inst Owner Change-23.91%

Ins Owners40.56%

Ins Owner Change-384.98%

Market Cap5.13M

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short Ratio0.01

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.2
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-2.46

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.32

FCFYN/A

OCF(TTM)-0.32

OCFYN/A

SpS0

BVpS0.35

TBVpS-1.12

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-121.79%
ROE	-580.23%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-48.88%

ROA(5y)N/A

ROE(3y)-207.06%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	2.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.25
Quick Ratio	0.25
Altman-Z	-3.4

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-509.26%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-2093.02%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y15.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-36.6%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-37.46%

OCF growth 3YN/A

OCF growth 5YN/A

IMPACT BIOMEDICAL INC (IBO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens